Bailey Pemberton
4 min read
IDEXX Laboratories has ridden a powerful multi year upswing, which naturally raises the question of whether the current share price lines up with the cash the business can generate. With the stock recently closing at US$689.65, investors are asking how much of its future cash flow story is already reflected in that figure.
-
Over the past 3 years, IDEXX Laboratories has delivered a 44.2% return. That puts real weight on whether that advance is grounded in its long term cash producing ability.
-
The company’s vet focused diagnostics model can support recurring cash inflows. As a result, the timing and durability of those cash streams matter a lot for any intrinsic value estimate based on its cash flows.
-
If you’d rather focus on earnings, this one’s for you. See what IDEXX Laboratories’s 46.0x P/E says about the price.
The issue now is whether IDEXX Laboratories’ current price is justified by its cash flows when tested against a Discounted Cash Flow (DCF) intrinsic value estimate.
If you want to stress test IDEXX Laboratories against other opportunities on the same research path, a focused stock screen of 35 high quality undervalued stocks can be a useful next step.
Has IDEXX Laboratories Run Too Far on Cash Flow?
The Discounted Cash Flow (DCF) model here is built around the cash IDEXX Laboratories can return to shareholders over time. Latest twelve month free cash flow sits at about $1.27b, which gives the valuation work a solid starting base rather than a turnaround story.
Analysts feeding into this 2 Stage Free Cash Flow to Equity model expect IDEXX Laboratories to continue generating higher free cash flow in absolute dollar terms, with projections stretching out over the next decade and then easing into more measured expansion. When those future streams are discounted back and compared with today’s traded level of US$689.65, the DCF output suggests the estimated intrinsic value is meaningfully below where the stock currently changes hands, so the market is placing a premium on the quality and duration of those cash flows. Find out what IDEXX Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.
The IDEXX Laboratories Narrative: What Would Justify Today’s Price?
Narratives on Simply Wall St pick up where the valuation puzzle leaves off for IDEXX Laboratories by spelling out what would need to happen to growth, margins and earnings for the stock to end up worth materially more or less than today’s price, and setting out the assumptions behind each fair value so you can track how those hold up as new results arrive on the Community page.